Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Sleep Disturbances Can Be Prospectively Observed in Patients with an Inactive Inflammatory Bowel Disease.

Bar-Gil Shitrit A, Chen-Shuali C, Adar T, Koslowsky B, Shteingart S, Paz K, Grisaru-Granovsky S, Goldin E, Epstein Shochet G, Shitrit D.

Dig Dis Sci. 2018 Jul 19. doi: 10.1007/s10620-018-5207-0. [Epub ahead of print]

PMID:
30027514
2.

A National Survey of Medical Coding and Billing Training in United States Dermatology Residency Programs.

Paz KB, Halverstam C, Rzepecki AK, McLellan BN.

J Drugs Dermatol. 2018 Jun 1;17(6):678-682.

PMID:
29879256
3.

Insulin stimulates PKCζ -mediated phosphorylation of insulin receptor substrate-1 (IRS-1): A self-attenuated mechanism to negatively regulate the function of IRS proteins.

Liu YF, Paz K, Herschkovitz A, Alt A, Tennenbaum T, Sampson SR, Ohba M, Kuroki T, LeRoith D, Zick Y.

J Biol Chem. 2018 May 11;293(19):7264. doi: 10.1074/jbc.W118.003466. No abstract available.

4.

MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice.

Wu Y, Schutt S, Paz K, Zhang M, Flynn RP, Bastian D, Sofi MH, Nguyen H, Dai M, Liu C, Chang YJ, Blazar BR, Yu XZ.

Blood. 2018 Apr 26;131(17):1974-1986. doi: 10.1182/blood-2017-06-789321. Epub 2018 Mar 12.

PMID:
29530952
5.

Systematic comparison of different techniques to measure hippocampal subfield volumes in ADNI2.

Mueller SG, Yushkevich PA, Das S, Wang L, Van Leemput K, Iglesias JE, Alpert K, Mezher A, Ng P, Paz K, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2017 Dec 27;17:1006-1018. doi: 10.1016/j.nicl.2017.12.036. eCollection 2018.

6.

Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients.

Du J, Flynn R, Paz K, Ren HG, Ogata Y, Zhang Q, Gafken PR, Storer BE, Roy NH, Burkhardt JK, Mathews W, Tolar J, Lee SJ, Blazar BR, Paczesny S.

Blood. 2018 Apr 12;131(15):1743-1754. doi: 10.1182/blood-2017-08-800623. Epub 2018 Jan 18.

PMID:
29348127
7.

Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients.

Friedman-Korn T, Livovsky DM, Maharshak N, Aviv Cohen N, Paz K, Bar-Gil Shitrit A, Goldin E, Koslowsky B.

Dig Dis Sci. 2018 Jan;63(1):198-203. doi: 10.1007/s10620-017-4833-2. Epub 2017 Nov 13.

PMID:
29134299
8.

Cefazolin Concentration in the Mediastinal Adipose Tissue of Patients Undergoing Cardiac Surgery.

Tchaick RM, Sá MPBO, Figueira FRM, Paz KC, Ferraz ÁAB, Moraes FR Neto.

Braz J Cardiovasc Surg. 2017 Jul-Aug;32(4):239-244. doi: 10.21470/1678-9741-2016-0031.

9.

Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.

Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris W, Maki R, Gaya A, Bedi A, Zacharoulis S, Ravi R, Wexler LH, Hoque MO, Rodriguez-Galindo C, Pass H, Peled N, Davies A, Morris R, Hidalgo M, Sidransky D.

Ann Oncol. 2017 Oct 1;28(10):2595-2605. doi: 10.1093/annonc/mdx416.

PMID:
28945830
10.

A critical role for donor-derived IL-22 in cutaneous chronic GVHD.

Gartlan KH, Bommiasamy H, Paz K, Wilkinson AN, Owen M, Reichenbach DK, Banovic T, Wehner K, Buchanan F, Varelias A, Kuns RD, Chang K, Fedoriw Y, Shea T, Coghill J, Zaiken M, Plank MW, Foster PS, Clouston AD, Blazar BR, Serody JS, Hill GR.

Am J Transplant. 2018 Apr;18(4):810-820. doi: 10.1111/ajt.14513. Epub 2017 Oct 24.

PMID:
28941323
11.

An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, Liu L, Bakoyannis G, Jiang D, Chu HW, Lobera M, Yang J, Wilkes DS, Du J, Gartlan K, Hill GR, MacDonald KP, Espada EL, Blanco P, Serody JS, Koreth J, Cutler CS, Antin JH, Soiffer RJ, Ritz J, Paczesny S, Blazar BR.

JCI Insight. 2017 Jun 15;2(12). pii: 92111. doi: 10.1172/jci.insight.92111. [Epub ahead of print]

12.

A Retrospective Comparison of Fecal Microbial Transplantation Methods for Recurrent Clostridium Difficile Infection.

Cohen NA, Livovsky DM, Yaakobovitch S, Ben Yehoyada M, Ben Ami R, Adler A, Guzner-Gur H, Goldin E, Santo ME, Halpern Z, Paz K, Maharshak N.

Isr Med Assoc J. 2016 Oct;18(10):594-599.

13.

Clarithromycin-Induced Mania after Triple Therapy for the Eradication of Helicobacter pylori.

Melamud B, Keller S, Mahamid M, Paz K, Goldin E.

Isr Med Assoc J. 2016 Aug;18(8):499-500. No abstract available.

14.

Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells.

Du J, Paz K, Thangavelu G, Schneidawind D, Baker J, Flynn R, Duramad O, Feser C, Panoskaltsis-Mortari A, Negrin RS, Blazar BR.

Blood. 2017 Jun 8;129(23):3121-3125. doi: 10.1182/blood-2016-11-752444. Epub 2017 Apr 17.

15.

Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.

Du J, Paz K, Flynn R, Vulic A, Robinson TM, Lineburg KE, Alexander KA, Meng J, Roy S, Panoskaltsis-Mortari A, Loschi M, Hill GR, Serody JS, Maillard I, Miklos D, Koreth J, Cutler CS, Antin JH, Ritz J, MacDonald KP, Schacker TW, Luznik L, Blazar BR.

Blood. 2017 May 4;129(18):2570-2580. doi: 10.1182/blood-2017-01-758854. Epub 2017 Mar 2.

16.

Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.

Teng PN, Bateman NW, Wang G, Litzi T, Blanton BE, Hood BL, Conrads KA, Ao W, Oliver KE, Darcy KM, McGuire WP, Paz K, Sidransky D, Hamilton CA, Maxwell GL, Conrads TP.

Hum Cell. 2017 Jul;30(3):226-236. doi: 10.1007/s13577-017-0162-1. Epub 2017 Mar 1.

PMID:
28251557
17.

Comparative mutational landscape analysis of patient-derived tumour xenografts.

Brait M, Izumchenko E, Kagohara LT, Long S, Wysocki PT, Faherty B, Fertig EJ, Khor TO, Bruckheimer E, Baia G, Ciznadija D, Sloma I, Ben-Zvi I, Paz K, Sidransky D.

Br J Cancer. 2017 Feb 14;116(4):515-523. doi: 10.1038/bjc.2016.450. Epub 2017 Jan 24.

18.

RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.

Sarfaty M, Moore A, Neiman V, Dudnik E, Ilouze M, Gottfried M, Katznelson R, Nechushtan H, Sorotsky HG, Paz K, Katz A, Saute M, Wolner M, Moskovitz M, Miller V, Elvin J, Lipson D, Ali S, Gutman LS, Dvir A, Gordon N, Peled N.

Clin Lung Cancer. 2017 Jul;18(4):e223-e232. doi: 10.1016/j.cllc.2016.09.003. Epub 2016 Oct 29.

PMID:
28082048
19.

MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated.

Smida M, Fece de la Cruz F, Kerzendorfer C, Uras IZ, Mair B, Mazouzi A, Suchankova T, Konopka T, Katz AM, Paz K, Nagy-Bojarszky K, Muellner MK, Bago-Horvath Z, Haura EB, Loizou JI, Nijman SM.

Nat Commun. 2016 Dec 6;7:13701. doi: 10.1038/ncomms13701.

20.

A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.

Bar-Gil Shitrit A, Koslowsky B, Livovsky DM, Shitrit D, Paz K, Adar T, Adler SN, Goldin E.

Scand J Gastroenterol. 2017 Mar;52(3):328-333. doi: 10.1080/00365521.2016.1253769. Epub 2016 Nov 13.

PMID:
27841040
21.

Health Disparity among Latina Women: Comparison with Non-Latina Women.

Paz K, Massey KP.

Clin Med Insights Womens Health. 2016 Jul 20;9(Suppl 1):71-4. doi: 10.4137/CMWH.S38488. eCollection 2016. Review.

22.

Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.

Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I.

Clin Cancer Res. 2016 Dec 15;22(24):6153-6163. Epub 2016 Jul 6.

23.
24.

Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.

Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, Vulic A, Luznik L, MacDonald KK, Hill GR, Nyuydzefe MS, Weiss JM, Chen W, Trzeciak A, Serody JS, Aguilar EG, Murphy WJ, Maillard I, Munn D, Koreth J, Cutler CS, Antin JH, Ritz J, Waksal SD, Zanin-Zhorov A, Blazar BR.

Blood. 2016 Apr 28;127(17):2144-54. doi: 10.1182/blood-2015-10-678706. Epub 2016 Mar 16.

25.

iPLEDGE Weaknesses: Is It Time to Address the Flaws?

Cyrulnik AA, Gewirtzman AJ, Paz KB, Glick JB, Anam AK, Carrasco DA, Shalita AR, Cohen SR.

J Drugs Dermatol. 2016 Jan;15(1):97-102.

PMID:
26741387
26.

Nitric Oxide-Releasing Nanoparticles Prevent Propionibacterium acnes-Induced Inflammation by Both Clearing the Organism and Inhibiting Microbial Stimulation of the Innate Immune Response.

Qin M, Landriscina A, Rosen JM, Wei G, Kao S, Olcott W, Agak GW, Paz KB, Bonventre J, Clendaniel A, Harper S, Adler BL, Krausz AE, Friedman JM, Nosanchuk JD, Kim J, Friedman AJ.

J Invest Dermatol. 2015 Nov;135(11):2723-2731. doi: 10.1038/jid.2015.277. Epub 2015 Jul 14.

27.

Milk derived colloid as a novel drug delivery carrier for breast cancer.

Hayashi M, Silanikove N, Chang X, Ravi R, Pham V, Baia G, Paz K, Brait M, Koch WM, Sidransky D.

Cancer Biol Ther. 2015;16(8):1184-93. doi: 10.1080/15384047.2015.1056416. Erratum in: Cancer Biol Ther. 2015;16(10):1567.

28.

Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.

Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, Vulic A, Du J, Panoskaltsis-Mortari A, Taylor PA, Poe JC, Serody JS, Murphy WJ, Hill GR, Maillard I, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Chao NJ, Clynes RA, Sarantopoulos S, Blazar BR.

Blood. 2015 Jun 25;125(26):4085-94. doi: 10.1182/blood-2014-08-595470. Epub 2015 Apr 7.

29.

TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus.

Doerner JL, Wen J, Xia Y, Paz KB, Schairer D, Wu L, Chalmers SA, Izmirly P, Michaelson JS, Burkly LC, Friedman AJ, Putterman C.

J Invest Dermatol. 2015 Aug;135(8):1986-1995. doi: 10.1038/jid.2015.124. Epub 2015 Mar 31.

30.

Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.

Bateman NW, Jaworski E, Ao W, Wang G, Litzi T, Dubil E, Marcus C, Conrads KA, Teng PN, Hood BL, Phippen NT, Vasicek LA, McGuire WP, Paz K, Sidransky D, Hamilton CA, Maxwell GL, Darcy KM, Conrads TP.

J Proteome Res. 2015 Apr 3;14(4):1900-10. doi: 10.1021/pr5012894. Epub 2015 Mar 19.

31.

Inflammatory bowel disease: an emergent disease among Ethiopian Jews migrating to Israel.

Bar-Gil Shitrit A, Koslowsky B, Kori M, Paz K, Adar T, Israeli E, Ben-Horin S, Berdichevski T, Coscas D, Gal E, Odes S, Shaul R, Ben-Ya'acov A, Goldin E.

Inflamm Bowel Dis. 2015 Mar;21(3):631-5. doi: 10.1097/MIB.0000000000000311.

PMID:
25581835
32.

Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients.

Zhu Q, Izumchenko E, Aliper AM, Makarev E, Paz K, Buzdin AA, Zhavoronkov AA, Sidransky D.

Hum Genome Var. 2015 Apr 2;2:15009. doi: 10.1038/hgv.2015.9. eCollection 2015.

33.

A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth.

Lebron MB, Brennan L, Damoci CB, Prewett MC, O'Mahony M, Duignan IJ, Credille KM, DeLigio JT, Starodubtseva M, Amatulli M, Zhang Y, Schwartz KD, Burtrum D, Balderes P, Persaud K, Surguladze D, Loizos N, Paz K, Kotanides H.

Cancer Biol Ther. 2014 Sep;15(9):1208-18. doi: 10.4161/cbt.29523. Epub 2014 Jun 12.

34.

Multicentric reticulohistiocytosis: contrasting presentations in 2 Hispanic patients.

Cyrulnik AA, Paz KB, Amin B, Mann RE, Krishnamurthy K, Friedman AJ.

Cutis. 2014 May;93(5):243-6.

PMID:
24897136
35.

The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.

Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K, Brait M, Hoque MO, Ling S, Bedi A, Sidransky D.

Cancer Res. 2014 Jul 15;74(14):3995-4005. doi: 10.1158/0008-5472.CAN-14-0110. Epub 2014 May 15. Erratum in: Cancer Res. 2014 Sep 1;74(17):4950-1.

36.

Patient-derived xenografts for individualized care in advanced sarcoma.

Stebbing J, Paz K, Schwartz GK, Wexler LH, Maki R, Pollock RE, Morris R, Cohen R, Shankar A, Blackman G, Harding V, Vasquez D, Krell J, Zacharoulis S, Ciznadija D, Katz A, Sidransky D.

Cancer. 2014 Jul 1;120(13):2006-15. doi: 10.1002/cncr.28696. Epub 2014 Apr 4. Erratum in: Cancer. 2014 Nov 15;120(22):3588. Zacharoulis, Stergios [added].

37.

KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.

Moran DM, Trusk PB, Pry K, Paz K, Sidransky D, Bacus SS.

Mol Cancer Ther. 2014 Jun;13(6):1611-24. doi: 10.1158/1535-7163.MCT-13-0649. Epub 2014 Mar 31.

38.

Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.

Garralda E, Paz K, López-Casas PP, Jones S, Katz A, Kann LM, López-Rios F, Sarno F, Al-Shahrour F, Vasquez D, Bruckheimer E, Angiuoli SV, Calles A, Diaz LA, Velculescu VE, Valencia A, Sidransky D, Hidalgo M.

Clin Cancer Res. 2014 May 1;20(9):2476-84. doi: 10.1158/1078-0432.CCR-13-3047. Epub 2014 Mar 14.

39.

Images in clinical medicine. Pneumatosis intestinalis.

Adar T, Paz K.

N Engl J Med. 2013 Apr 11;368(15):e19. doi: 10.1056/NEJMicm1205591. No abstract available.

40.

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports.

Mahamid M, Paz K, Reuven M, Safadi R.

Int J Gen Med. 2011;4:657-60. doi: 10.2147/IJGM.S23920. Epub 2011 Sep 7.

41.

Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.

Prewett M, Bassi R, Paz K, Amatulli M, Deevi D, Li H, Wang S, Witte L, Samakoglu S, Tonra JR.

Anticancer Res. 2011 Jun;31(6):2149-60.

PMID:
21737635
42.

Targeted therapy of the insulin-like growth factor-1 receptor in cancer.

Paz K, Hadari YR.

Comb Chem High Throughput Screen. 2008 Jan;11(1):62-9. Review.

PMID:
18220543
43.
44.

Fecal calprotectin as a predictor of abnormal colonic histology.

Shitrit AB, Braverman D, Stankiewics H, Shitrit D, Peled N, Paz K.

Dis Colon Rectum. 2007 Dec;50(12):2188-93.

PMID:
17963005
45.

Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.

Leslie K, Lang C, Devgan G, Azare J, Berishaj M, Gerald W, Kim YB, Paz K, Darnell JE, Albanese C, Sakamaki T, Pestell R, Bromberg J.

Cancer Res. 2006 Mar 1;66(5):2544-52.

46.

Recent advances in targeted therapy of human myelogenous leukaemia.

Paz K, Zhu Z.

Expert Opin Ther Targets. 2005 Dec;9(6):1147-63. Review.

PMID:
16300467
47.

Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation.

Paz K, Brennan LA, Iacolina M, Doody J, Hadari YR, Zhu Z.

Mol Cancer Ther. 2005 Nov;4(11):1801-9.

48.
49.

Serine phosphorylation proximal to its phosphotyrosine binding domain inhibits insulin receptor substrate 1 function and promotes insulin resistance.

Liu YF, Herschkovitz A, Boura-Halfon S, Ronen D, Paz K, Leroith D, Zick Y.

Mol Cell Biol. 2004 Nov;24(21):9668-81.

50.

Transformation fingerprint: induced STAT3-C, v-Src and Ha-Ras cause small initial changes but similar established profiles in mRNA.

Paz K, Socci ND, van Nimwegen E, Viale A, Darnell JE.

Oncogene. 2004 Nov 4;23(52):8455-63.

PMID:
15378015

Supplemental Content

Support Center